Table 5. Simulation based AUC for 300.
| Dose = 300 mg daily | Dose = 450 mg daily | Dose = 600 mg daily | ||||||
| Area Under the curve (µg/L·h) x104 | ||||||||
| number of obsa | Mean (±SD) | 95% CI | Mean (±SD) | 95% CI | Mean (±SD) | 95% CI | ||
| All participants | 47000 | 3.63 (1.93) | 1.57–7.58 | 5.44 (2.90) | 2.35–11.06 | 7.25 (3.86) | 3.14–14.75 | |
| ABCB1(c.4046A>G) wt | CYP2B6*6 | |||||||
| *1/*1 | 17500 | 2.5 (0.94) | 1.28–5.41 | 3.75 (1.41) | 1.92–3.50 | 5.0 (1.88) | 2.56–8.49 | |
| *1/*6 | 2000 | 3.16 (1.17) | 1.63–5.34 | 4.74 (1.75) | 2.45–8.01 | 6.32 (2.34) | 3.27–10 68 | |
| *6/*6 | 10500 | 5.57 (2.14) | 2.85–9.53 | 8.36 (3.21) | 4.27–14.29 | 11.14 (4.28) | 5.7–19.05 | |
| ABCB1(c.4046A>G) Mut | ||||||||
| *1/*1 | 4000 | 3.20 (1.21) | 1.65–5.41 | 4.80 (1.81) | 2.48–8.11 | 6.41 (2.41) | 3.31–10.81 | |
| *1/*6 | 9000 | 4.05 (1.54) | 2.10–7.05 | 6.07 (2.32) | 3.14–10.58 | 8.10 (3. 09) | 4.19–14.10 | |
| *6/*6 | 4000 | 7.12 (2.72) | 3.63–12.20 | 10.67 (4.09) | 5.45–18.30 | 14.23 (5.45) | 7.26–24.40 | |
a
The frequency of each group in these simulations reflects the proportional frequency of the groups in the observed patient dataset.